Safety of moclobemide taken in overdose for attempted suicide

  title={Safety of moclobemide taken in overdose for attempted suicide},
  author={W. Hetzel},
  • W. Hetzel
  • Published 2005
  • Medicine
  • Psychopharmacology
Moclobemide is a reversible inhibitor of the monoamine oxidase type A. In clinical studies, more than 3900 patients have been treated with moclobemide for depression. Eighteen of these patients attempted suicide by overdosing moclobemide with or without other drugs. All patients recovered fully without leaving signs of cardio-or hepatotoxicity. Moclobemide can safely be prescribed for in- and out-patient treatment of depression. 
Death following acute poisoning by moclobemide.
It was concluded that the manner ofdeath was suicide and that the unique cause of death was massive ingestion of moclobemide, and the other xenobiotics were considered of little toxicological relevance. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Death Following Moclobemide and Venlafaxine Overdose
A case of suspected serotonin toxicity causing death following the ingestion of moclobemide and venlafaxine is presented, only the second reported fatality following venlaphoresis, diarrhea and labored breathing immediately prior to death. Expand
Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.
Moclobemide overdose in combination with a serotonergic agent (even in normal therapeutic doses) can cause severe serotonin toxicity, and the elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses. Expand
Serotonin syndrome and drug combinations: focus on MAOI and RIMA
A spectrum of serotonergic hyperactivity, through to a defined serotonin syndrome, may arise from the use or combination of any serotomimetic substance, as this is a consequence of the mechanism involved, rather than the use of any specific product such as the new antidepressants. Expand


Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated. Expand
Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
The reversible MAO-A inhibitors moclobemide and brofaromine, due to their well-documented safety characteristics, to their lack of anticholinergic-effects and to their good tolerability, will provide innovative tools for clarifying the role of MAO -A inhibitors in the treatment of endogenous and atypical depressive states. Expand
Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
The results suggest that the two reversible MAO-A inhibitors Mocl and Brof may lessen the liability to TYR-related hypertensive reactions. Expand
Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders
In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia,Expand
Fatal toxicity of antidepressant drugs in overdose.
Of these newer drugs, maprotiline had a fatal toxicity index similar to that of the older tricyclic antidepressants, while the other newly introduced drugs had lower toxicity indices, with those for mianserin, nomifensine, trazodone, and viloxazine reaching significance. Expand
Incidence and evaluation of risk of suicide in depression
  • 1987